SWAN Welcomes Goodwin Procter LLP as Newest Sponsor

February 21, 2023
News, Sponsors

SWAN is pleased to announce that Goodwin Procter LLP has joined SWAN as our newest sponsor.

Goodwin’s nearly 2,000 lawyers focus on building authentic, long-term relationships with clients, who are some of the world’s most successful and innovative investors, entrepreneurs, and disruptors at the convergence of and within the life sciences, private equity, real estate, technology, and financial industries. Their immersive understanding of their clients’ industries – combined with their expertise across high-stakes litigation and dispute resolution, world-class regulatory compliance and advisory services, and complex transactions – sets them apart. Goodwin Law has offices in various cities in North America, Europe, and Asia.

 

Portfolio company Yotta Energy Selected to Participate in The Clean Fight New York

January 5, 2023
, , News

Congratulations to SWAN portfolio company Yotta Energy, which was recently selected as one of 10 companies to participate in The Clean Fight New York. The Clean Fight New York is a not-for-profit climate tech organization, powered by New Energy Nexus, that helps scale growth-stage climate tech companies in New York. The third chapter of The Clean Fight is focused on battery and energy storage solutions that can help speed the clean energy transition.

SWAN announces investment in Relavo

December 23, 2022
News, Recent Investment

SWAN is pleased to announce an initial investment in Relavo.

Relavo is a medical device company that is changing the way that kidney failure patients receive treatment. Founded by an all-female team of biomedical engineers from Johns Hopkins University, Relavo is seeking to make home dialysis more accessible by minimizing the risk of infection with their technology, the PeritoneX. The PeritoneX is a novel connection device that reduces the risk of infection in peritoneal dialysis. Rather than connecting tubes directly, patients will connect them to the PeritoneX, which then internally disinfects the connected tubes with an antimicrobial solution. By reducing the risk of infection, patients will receive safer treatment.

Valerie Tompson to lead SWAN’s Houston Chapter

August 27, 2022
News

SWAN Impact Network is pleased to announce that Valerie Tompson has been named to serve as the Chapter Lead of the Houston branch and has also joined SWAN’s Board of Directors.

Valerie has worked as a physician assistant and currently serves as the Executive Director at City Church in Houston. With a blend of medical experience, public accounting, a recent MBA from Duke University, and non-profit management experience, Valerie gathers and analyzes data and makes executable plans for innovative, efficient processes that directly impact the bottom line. She brings an intensity and stamina of effort to her work with attention to detail as well as an ability to simplify complicated ideas and build trusting relationships. Valerie enjoys getting up-to-speed quickly and continually learning new things to stay on the cutting edge. Much of her professional and personal time has been spent in roles helping organizations make an impact.

Outside of work, Valerie enjoys spending time with her family. Her husband Matt is a Physician who practices in the Houston Medical Center, and they have three children who range from middle to graduate school. Traveling (and eating), reading, and running fill up her additional time. Valerie has served in many roles in her children’s schools in Houston, including the chair of the Parent Guild at St. John’s School and PTO president at Roberts Elementary.

SWAN announces follow-on investment in Sonnest

April 12, 2022
News, Recent Investment

SWAN is pleased to announce a follow-on investment in Sonnest.

Sonnest is transforming cardiac ultrasound. Their Electrast™ is the first electrically sensitive imaging agent for assessing and monitoring the perfusion, structure, and function of the heart, allowing low cost ultrasound procedures to provide information only previously available from much higher cost scans. Electrast™ is a contrast agent that activates with ultrasound and the heart’s local electric field if the heart tissue is perfused and viable.

SWAN previously invested in Sonnest in February and May 2021.

1 2 3 4